Lipopolysaccharides (LPS) are the main components of the external leaflet of the Gram-negative outer membrane and consist of three different moieties: lipid A, core oligosaccharide, and O-polysaccharide. The lipid A is a glucosamine disaccharide with different levels of acylation and phosphorylation, beside carrying, in certain cases, additional substituents on the sugar backbone. It is also the main immunostimulatory part of the LPS, as its recognition by the host immune system represents a fundamental event for detection of perilous microorganisms. Moreover, an uncontrolled immune response caused by a large amount of circulating LPS can lead to dramatic outcomes for human health, such as septic shock. The immunostimulant properties of an LPS incredibly vary depending on lipid A chemical structure, and for this reason, natural and synthetic variants of the lipid A are under study to develop new drugs that mimic or antagonise its natural effects. Here, we review past and recent findings on the lipid A as an antibiotic target and immune-therapeutic molecule, with a special attention on the crucial role of the chemical structure and its exploitation for conceiving novel strategies for treatment of several immune-related pathologies.

Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics / GARCIA DEL VELLO MORENO, Pilar; Di Lorenzo, F.; Zucchetta, D.; Zamyatina, A.; De Castro, C.; Molinaro, A.. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 230:(2022), p. 107970. [10.1016/j.pharmthera.2021.107970]

Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics

Garcia Vello Pilar;Di Lorenzo F.;De Castro C.;Molinaro A.
2022

Abstract

Lipopolysaccharides (LPS) are the main components of the external leaflet of the Gram-negative outer membrane and consist of three different moieties: lipid A, core oligosaccharide, and O-polysaccharide. The lipid A is a glucosamine disaccharide with different levels of acylation and phosphorylation, beside carrying, in certain cases, additional substituents on the sugar backbone. It is also the main immunostimulatory part of the LPS, as its recognition by the host immune system represents a fundamental event for detection of perilous microorganisms. Moreover, an uncontrolled immune response caused by a large amount of circulating LPS can lead to dramatic outcomes for human health, such as septic shock. The immunostimulant properties of an LPS incredibly vary depending on lipid A chemical structure, and for this reason, natural and synthetic variants of the lipid A are under study to develop new drugs that mimic or antagonise its natural effects. Here, we review past and recent findings on the lipid A as an antibiotic target and immune-therapeutic molecule, with a special attention on the crucial role of the chemical structure and its exploitation for conceiving novel strategies for treatment of several immune-related pathologies.
2022
Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics / GARCIA DEL VELLO MORENO, Pilar; Di Lorenzo, F.; Zucchetta, D.; Zamyatina, A.; De Castro, C.; Molinaro, A.. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 230:(2022), p. 107970. [10.1016/j.pharmthera.2021.107970]
File in questo prodotto:
File Dimensione Formato  
144_pharmacology_1-s2.0-S0163725821001728-main_final.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 2.1 MB
Formato Adobe PDF
2.1 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/865765
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 37
social impact